Abstract
The treatment environment for chronic hepatitis C has undergone a revolution, particularly in genotype 1. Gone are interferon-based therapy and its associated tolerability challenges, inadequate response rates and numerous baseline factors that affect response to therapy. New and emerging treatment regimens employ all-oral combinations of direct-acting antiviral agents, and results of clinical trials suggest that these regimens routinely achieve cure rates >90%, even in patients who failed prior interferon-based triple therapy. In 2015, three all-oral FDA-approved regiments will be available for genotype 1 (sofosbuvir /ledipasvir, sofosbuvir/simeprevir, and paritaprevir/r/ombitasvir/dasabuvir). Furthermore, new treatment combinations appear to be more tolerable and require shorter duration of therapy. We provide an overview of the classes of direct-acting antiviral agents (DAAs), the clinical factors affecting their integration into combination therapies and recent findings from trials of such combination therapies in patients with genotype 1 HCV infection.
Original language | English (US) |
---|---|
Pages (from-to) | 861-870 |
Number of pages | 10 |
Journal | Journal of Viral Hepatitis |
Volume | 22 |
Issue number | 11 |
DOIs | |
State | Published - Nov 2015 |
Keywords
- GS-9669
- NS5A inhibitor
- RNA polymerase inhibitor
- asunaprevir
- beclabuvir
- daclatasvir
- dasabuvir
- direct-acting antivirals
- elbasvir
- faldaprevir
- genotype 1
- grazoprevir
- hepatitis C
- ledipasvir
- ombitasvir
- paritaprevir
- protease inhibitor
- resistance-associated variants
- ribavirin
- simeprevir
- sofosbuvir
ASJC Scopus subject areas
- Infectious Diseases
- Virology
- Hepatology